Revvity

Revvity (RVTY) is a publicly traded company in the Health Care sector, specifically within the Health Care Equipment industry. Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.

The company reports trailing twelve-month revenue of $741.21M and net income of $40.72M.

Key metrics include a return on equity of 0.6%, a debt-to-equity ratio of 0.67.

Investors tracking RVTY can follow price movements, analyst estimates, and fundamental changes directly through FINOTAUR's research tools.